EP2391372A4 - Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition - Google Patents

Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition

Info

Publication number: EP2391372A4
Authority: EP; European Patent Office
Prior art keywords: inhibition; methods; binding protein; estrogen receptor; positive cancer
Prior art date: 2009-01-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP10736464.8A

Other languages

German (de)

French (fr)

Other versions

EP2391372A1 (en

Inventor

David Kiewlich

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Healthcare LLC

Original Assignee

Bayer Healthcare LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-30

Filing date

2010-01-29

Publication date

2013-07-03

2010-01-29 Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC

2011-12-07 Publication of EP2391372A1 publication Critical patent/EP2391372A1/en

2013-07-03 Publication of EP2391372A4 publication Critical patent/EP2391372A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP10736464.8A 2009-01-30 2010-01-29 Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition Withdrawn EP2391372A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US14851809P	2009-01-30	2009-01-30
PCT/US2010/022552 WO2010088498A1 (en)	2009-01-30	2010-01-29	Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition

Publications (2)

Publication Number	Publication Date
EP2391372A1 EP2391372A1 (en)	2011-12-07
EP2391372A4 true EP2391372A4 (en)	2013-07-03

Family

ID=42396035

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP10736464.8A Withdrawn EP2391372A4 (en)	2009-01-30	2010-01-29	Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition

Country Status (3)

Country	Link
EP (1)	EP2391372A4 (en)
CA (1)	CA2749947A1 (en)
WO (1)	WO2010088498A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20130115108A (en)	2010-05-28	2013-10-21	더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템	Oligo-benzamide compounds and their use
WO2012109238A2 (en)	2011-02-07	2012-08-16	President And Fellows Of Harvard College	Methods for increasing immune responses using agents that directly bind to and activate ire-1
GB201109965D0 (en) *	2011-06-10	2011-07-27	Cancer Res Inst Royal	Materials and methods for treating estrogen receptor alpher(ER) positive cancer
WO2013078277A1 (en)	2011-11-23	2013-05-30	The Board Of Regents Of The University Of Texas System	Oligo-benzamide compounds and their use in treating cancers
WO2013078288A1 (en) *	2011-11-23	2013-05-30	The Board Of Regents Of The University Of Texas System	Oligo-benzamide compounds for use in treating cancers
US20150018406A1 (en) *	2012-03-09	2015-01-15	Cornell University	Modulation of breast cancer growth by modulation of xbp1 activity
DK3049521T3 (en)	2013-09-25	2019-04-23	Univ Cornell	Compounds for inducing antitumor immunity and methods thereof
WO2020011909A1 (en) *	2018-07-11	2020-01-16	Secarna Pharmaceuticals Gmbh & Co. Kg	Nucleic acid polymers inhibiting the expression of xbp1
US20230026844A1 (en) *	2019-12-12	2023-01-26	University Of Maryland, Baltimore	Inhibitors of Cancer Biomarkers and Uses Thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004020610A2 (en) *	2002-08-30	2004-03-11	President And Fellows Of Harvard College	Methods and compositions for modulating xbp-1 activity
WO2007101224A2 (en) *	2006-02-27	2007-09-07	The Board Of Trustees Of The Leland Stanford Junior University	Inhibitors of the unfolded protein response and methods for their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2396062C (en) *	1999-12-30	2009-11-17	President And Fellows Of Harvard College	Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or t cell subset activity by modulation of xbp-1 activity
CA2430981A1 (en) *	2000-12-08	2002-06-13	Francois Bertucci	Gene expression profiling of primary breast carcinomas using arrays of candidate genes
JP2008538284A (en) *	2005-04-04	2008-10-23	ベリデックス・エルエルシー	Laser microdissection and microarray analysis of breast tumors reveals genes and pathways associated with estrogen receptors

2010
- 2010-01-29 CA CA2749947A patent/CA2749947A1/en not_active Abandoned
- 2010-01-29 WO PCT/US2010/022552 patent/WO2010088498A1/en not_active Ceased
- 2010-01-29 EP EP10736464.8A patent/EP2391372A4/en not_active Withdrawn

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004020610A2 (en) *	2002-08-30	2004-03-11	President And Fellows Of Harvard College	Methods and compositions for modulating xbp-1 activity
WO2007101224A2 (en) *	2006-02-27	2007-09-07	The Board Of Trustees Of The Leland Stanford Junior University	Inhibitors of the unfolded protein response and methods for their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B. P. GOMEZ ET AL: "Human X-Box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines", THE FASEB JOURNAL, vol. 21, no. 14, 20 July 2007 (2007-07-20), pages 4013 - 4027, XP055061962, ISSN: 0892-6638, DOI: 10.1096/fj.06-7990com *
See also references of WO2010088498A1 *

Also Published As

Publication number	Publication date
CA2749947A1 (en)	2010-08-05
WO2010088498A1 (en)	2010-08-05
EP2391372A1 (en)	2011-12-07

Publication	Publication Date	Title
IL257418A (en)	2018-04-30	Methods for treating dependence
EP2391372A4 (en)	2013-07-03	Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition
IL219914A (en)	2015-10-29	1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
PL3517534T3 (en)	2024-06-24	Compounds useful for treating cancer
PT2242773T (en)	2017-09-15	Monoclonal antibodies for tumor treatment
PT2252148T (en)	2020-01-23	Methods for treating bowel diseases
PL2478907T3 (en)	2021-10-25	Compositions for treating cancer
AP2011005956A0 (en)	2011-10-31	Methods of treatment for solid tumors.
SI2173379T1 (en)	2015-12-31	Compositions and methods for treating and diagnosing cancer
PT2310034E (en)	2014-06-05	Peptides for treating beta-amyloidoses
IL197633A0 (en)	2011-08-01	Methods for treating cancer with mva
EP2262366A4 (en)	2012-02-22	Compounds and methods for treating estrogen receptor-related diseases
EP2282826A4 (en)	2012-12-05	Methods for treating odors
IL219331A0 (en)	2012-06-28	Method for treating androgrn receptor positive cancers
EP2125887A4 (en)	2010-11-10	Compositions and methods for diagnosing and treating cancer
ZA201203449B (en)	2013-01-31	Sulfoxide derivatives for treating tumors
IL213398A0 (en)	2011-07-31	Compounds for treating cancer
EP2155249A4 (en)	2011-11-16	Compositions and methods for diagnosing and treating cancer
PT2299822T (en)	2017-10-30	Method for treating neurodegenerative dysfunction
EP2144888A4 (en)	2012-10-03	Methods for treating cancer
EP2477635A4 (en)	2013-03-27	Methods for treating brain tumors
EP2374463A4 (en)	2012-11-07	Composition for improving radiotherapy for cancer
PL2248115T3 (en)	2015-10-30	Adjusting drum for product-delivering spiral
PL2949361T3 (en)	2017-09-29	C-19 steroids for treating cellulite
EP2528613A4 (en)	2013-06-05	Method for treating liver disorders with receptor associated protein ( irp) peptide-fucosidase inhibitor conjugates

Legal Events

Date	Code	Title	Description
2011-11-04	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2011-12-07	17P	Request for examination filed	Effective date: 20110830
2011-12-07	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
2012-05-09	DAX	Request for extension of the european patent (deleted)
2013-07-03	A4	Supplementary search report drawn up and despatched	Effective date: 20130603
2013-07-03	RIC1	Information provided on ipc code assigned before grant	Ipc: C12N 15/113 20100101ALI20130527BHEP Ipc: A61K 31/7088 20060101ALI20130527BHEP Ipc: A61K 31/00 20060101ALI20130527BHEP Ipc: A61K 31/70 20060101AFI20130527BHEP Ipc: A61K 39/395 20060101ALI20130527BHEP Ipc: A61K 35/12 20060101ALI20130527BHEP
2013-12-13	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2014-01-15	18D	Application deemed to be withdrawn	Effective date: 20130801